Comparison of zotarolimus-eluting and sirolimus-eluting stents in patients with native coronary artery disease: a randomized controlled trial
David E Kandzari, Martin B Leon, Jeffrey J Popma, Peter J Fitzgerald, Charles O'Shaughnessy, Michael W Ball, Mark Turco, Robert J Applegate, Paul A Gurbel, Mark G Midei, Sejal S Badre, Laura Mauri, Kweli P Thompson, LeRoy A LeNarz, Richard E Kuntz, ENDEAVOR III Investigators, David E Kandzari, Martin B Leon, Jeffrey J Popma, Peter J Fitzgerald, Charles O'Shaughnessy, Michael W Ball, Mark Turco, Robert J Applegate, Paul A Gurbel, Mark G Midei, Sejal S Badre, Laura Mauri, Kweli P Thompson, LeRoy A LeNarz, Richard E Kuntz, ENDEAVOR III Investigators
Abstract
Objectives: This trial examined the relative clinical efficacy, angiographic outcomes, and safety of zotarolimus-eluting coronary stents (ZES) with a phosphorylcholine polymer versus sirolimus-eluting stents (SES).
Background: Whether a cobalt-based alloy stent coated with the novel antiproliferative agent, zotarolimus, and a phosphorylcholine polymer may provide similar angiographic and clinical benefit compared with SES is undetermined.
Methods: A prospective, multicenter, 3:1 randomized trial was conducted to evaluate the safety and efficacy of ZES (n = 323) relative to SES (n = 113) in 436 patients undergoing elective percutaneous revascularization of de novo native coronary lesions with reference vessel diameters between 2.5 mm and 3.5 mm and lesion length > or =14 mm and < or =27 mm. The primary end point was 8-month angiographic in-segment late lumen loss.
Results: Angiographic in-segment late lumen loss was significantly higher among patients treated with ZES compared with SES (0.34 +/- 0.44 mm vs. 0.13 +/- 0.32 mm, respectively; p < 0.001). In-hospital major adverse cardiac events were significantly lower among patients treated with ZES (0.6% vs. 3.5%, p = 0.04). In-segment binary angiographic restenosis was also higher in the ZES cohort (11.7% vs. 4.3%, p = 0.04). Total (clinically and non-clinically driven) target lesion revascularization rates at 9 months were 9.8% and 3.5% for the ZES and SES groups, respectively (p = 0.04). However, neither clinically driven target lesion revascularization (6.3% zotarolimus vs. 3.5% sirolimus, p = 0.34) nor target vessel failure (12.0% zotarolimus vs. 11.5% sirolimus, p = 1.0) differed significantly.
Conclusions: Compared with SES, treatment with a phosphorylcholine polymer-based ZES is associated with significantly higher late lumen loss and binary restenosis at 8-month angiographic follow-up. (The Endeavor III CR; https://ichgcp.net/clinical-trials-registry/NCT00265668?order=1?).
Source: PubMed